MA32642B1 - Amides utiles en therapie - Google Patents
Amides utiles en therapieInfo
- Publication number
- MA32642B1 MA32642B1 MA33710A MA33710A MA32642B1 MA 32642 B1 MA32642 B1 MA 32642B1 MA 33710 A MA33710 A MA 33710A MA 33710 A MA33710 A MA 33710A MA 32642 B1 MA32642 B1 MA 32642B1
- Authority
- MA
- Morocco
- Prior art keywords
- optionally substituted
- substituents
- alkyl
- independently selected
- oxo
- Prior art date
Links
- 150000001408 amides Chemical class 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 206010046798 Uterine leiomyoma Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010260 leiomyoma Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9790208P | 2008-09-18 | 2008-09-18 | |
| PCT/IB2009/054038 WO2010032200A1 (en) | 2008-09-18 | 2009-09-16 | Amide compounds useful in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA32642B1 true MA32642B1 (fr) | 2011-09-01 |
Family
ID=41269630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA33710A MA32642B1 (fr) | 2008-09-18 | 2011-03-18 | Amides utiles en therapie |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8232269B2 (OSRAM) |
| EP (1) | EP2350017A1 (OSRAM) |
| JP (1) | JP2012502975A (OSRAM) |
| KR (1) | KR20110044304A (OSRAM) |
| CN (1) | CN102159548A (OSRAM) |
| AP (1) | AP2011005611A0 (OSRAM) |
| AU (1) | AU2009294290B2 (OSRAM) |
| BR (1) | BRPI0918935A2 (OSRAM) |
| CA (1) | CA2735931A1 (OSRAM) |
| CL (1) | CL2011000570A1 (OSRAM) |
| CO (1) | CO6351734A2 (OSRAM) |
| DO (1) | DOP2011000083A (OSRAM) |
| EA (1) | EA201100368A1 (OSRAM) |
| EC (1) | ECSP11010901A (OSRAM) |
| IL (1) | IL211479A0 (OSRAM) |
| MA (1) | MA32642B1 (OSRAM) |
| MX (1) | MX2011002899A (OSRAM) |
| PE (1) | PE20110793A1 (OSRAM) |
| WO (1) | WO2010032200A1 (OSRAM) |
| ZA (1) | ZA201102690B (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2541295T3 (es) * | 2011-04-21 | 2015-07-17 | Orion Corporation | Carboxamidas que modulan el receptor de andrógenos |
| JP6046134B2 (ja) * | 2011-07-21 | 2016-12-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 小分子によるヒト癌におけるｇｌｉタンパク質の標的化 |
| WO2013123240A1 (en) | 2012-02-17 | 2013-08-22 | Eisai R&D Management Co., Ltd | Methods and compounds useful in the synthesis of orexin-2 receptor antagonists |
| EP2700635A1 (en) | 2012-08-20 | 2014-02-26 | Basf Se | 5-Trifluoromethylpyrazole amides having herbicidal activity |
| JP2016505049A (ja) | 2013-01-23 | 2016-02-18 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 小分子によるヒト癌におけるｇｌｉタンパク質のターゲティング方法 |
| SI3290421T1 (sl) | 2013-02-22 | 2019-03-29 | Pfizer Inc. | Kombinacija derivatov pirolo (2,3-D)pirimidina z enim ali več dodatnimi sredstvi za zaviranje z janusom povezane kinaze (JAK) |
| WO2014143617A1 (en) * | 2013-03-14 | 2014-09-18 | Teva Women's Health, Inc. | Deuterium-enriched tanaproget and processes for its preparation |
| WO2016024185A1 (en) | 2014-08-12 | 2016-02-18 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase |
| WO2017221144A1 (en) * | 2016-06-20 | 2017-12-28 | Dr. Reddy's Laboratories Limited | Process for the preparation of elagolix sodium and its polymorph |
| CN108623446A (zh) * | 2017-03-24 | 2018-10-09 | 北京艾德旺科技发展有限公司 | 一种合成3，3-二氟环丁烷甲酸的方法 |
| WO2020198583A1 (en) | 2019-03-27 | 2020-10-01 | Insilico Medicine Ip Limited | Bicyclic jak inhibitors and uses thereof |
| EP4053124A1 (en) * | 2019-10-28 | 2022-09-07 | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | Five-membered heterocyclic oxocarboxylic acid compound and medical use thereof |
| WO2023217203A2 (zh) * | 2022-05-12 | 2023-11-16 | 西北农林科技大学 | 二苯基吡唑类化合物的制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1874732A1 (en) * | 2005-04-20 | 2008-01-09 | Pfizer Limited | Pyrazole derivatives as progesterone receptor antagonists |
| US7947707B2 (en) * | 2005-10-07 | 2011-05-24 | Kissei Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same |
-
2009
- 2009-09-16 KR KR1020117006161A patent/KR20110044304A/ko not_active Ceased
- 2009-09-16 WO PCT/IB2009/054038 patent/WO2010032200A1/en not_active Ceased
- 2009-09-16 CA CA2735931A patent/CA2735931A1/en not_active Abandoned
- 2009-09-16 EP EP09787204A patent/EP2350017A1/en not_active Withdrawn
- 2009-09-16 AU AU2009294290A patent/AU2009294290B2/en not_active Expired - Fee Related
- 2009-09-16 JP JP2011527444A patent/JP2012502975A/ja not_active Withdrawn
- 2009-09-16 AP AP2011005611A patent/AP2011005611A0/xx unknown
- 2009-09-16 PE PE2011000628A patent/PE20110793A1/es not_active Application Discontinuation
- 2009-09-16 EA EA201100368A patent/EA201100368A1/ru unknown
- 2009-09-16 CN CN2009801364939A patent/CN102159548A/zh active Pending
- 2009-09-16 BR BRPI0918935A patent/BRPI0918935A2/pt not_active IP Right Cessation
- 2009-09-16 MX MX2011002899A patent/MX2011002899A/es not_active Application Discontinuation
- 2009-09-17 US US12/561,398 patent/US8232269B2/en not_active Expired - Fee Related
-
2011
- 2011-02-28 IL IL211479A patent/IL211479A0/en unknown
- 2011-03-17 DO DO2011000083A patent/DOP2011000083A/es unknown
- 2011-03-17 EC EC2011010901A patent/ECSP11010901A/es unknown
- 2011-03-17 CL CL2011000570A patent/CL2011000570A1/es unknown
- 2011-03-18 MA MA33710A patent/MA32642B1/fr unknown
- 2011-03-25 CO CO11036952A patent/CO6351734A2/es not_active Application Discontinuation
- 2011-04-11 ZA ZA2011/02690A patent/ZA201102690B/en unknown
-
2012
- 2012-06-18 US US13/525,893 patent/US20120316150A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009294290B2 (en) | 2012-08-30 |
| US20100249091A1 (en) | 2010-09-30 |
| US8232269B2 (en) | 2012-07-31 |
| AU2009294290A1 (en) | 2010-03-25 |
| EP2350017A1 (en) | 2011-08-03 |
| WO2010032200A1 (en) | 2010-03-25 |
| IL211479A0 (en) | 2011-05-31 |
| US20120316150A1 (en) | 2012-12-13 |
| PE20110793A1 (es) | 2011-10-31 |
| BRPI0918935A2 (pt) | 2015-12-01 |
| ECSP11010901A (es) | 2011-04-29 |
| CA2735931A1 (en) | 2010-03-25 |
| MX2011002899A (es) | 2011-04-11 |
| EA201100368A1 (ru) | 2011-12-30 |
| DOP2011000083A (es) | 2011-03-31 |
| CN102159548A (zh) | 2011-08-17 |
| ZA201102690B (en) | 2011-12-28 |
| CO6351734A2 (es) | 2011-12-20 |
| AP2011005611A0 (en) | 2011-04-30 |
| JP2012502975A (ja) | 2012-02-02 |
| KR20110044304A (ko) | 2011-04-28 |
| CL2011000570A1 (es) | 2011-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA32642B1 (fr) | Amides utiles en therapie | |
| EA200601830A1 (ru) | Ортозамещённые арильные или гетероарильные амидные соединения | |
| MX2009008465A (es) | Nuevas 2-aminooxazolinas como ligandos de taar1. | |
| MY142807A (en) | Benzimidazole derivative and use thereof. | |
| EP1724262A4 (en) | 1- (2H) -ISOCHINOLONDERIVAT | |
| PE20040164A1 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas | |
| MA30483B1 (fr) | Utilisation de biphenylamides d'acide arylcarboxylique pour le traitement de semences. | |
| MY150269A (en) | Novel phenylpyrrole derivative | |
| MY177250A (en) | Novel nicotinamide derivative or salt thereof | |
| MA33851B1 (fr) | Compose heterocyclique contenant de l'azote et fongicide agricole | |
| MA38540A1 (fr) | Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6 | |
| ATE538099T1 (de) | 2-ä1-phenyl-5-hydroxy-4-alpha-methyl- hexahydrocyclopentaäfüindazol-5- ylüethylphenylderivate als glucocorticoidrezeptorliganden | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| AR071792A1 (es) | Antagonistas nitrogenados del receptor de glucagon, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento y/o prevencion de la diabetes tipo ii y afecciones relacionadas. | |
| MA28973B1 (fr) | Compose heterocyclique fusionne | |
| NZ610312A (en) | 6-amino-2-phenylamino-1h-benzimidazole-5-carboxamide- derivatives and their use as microsomal prostaglandin e2 synthase-1 inhibitors | |
| MA32088B1 (fr) | Dérivés bicycliques de carboxamides azabicycliques, leur préparation et leur application en thérapeutique | |
| JP2010535722A5 (OSRAM) | ||
| MA32089B1 (fr) | Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique | |
| EA200401613A1 (ru) | Лекарственное средство для лечения рака | |
| TW200640862A (en) | Pyridyl acetic acid compounds | |
| BRPI0513777A (pt) | composto ou um sal do mesmo, composição farmacêutica, e, uso de um composto ou de um sal do mesmo | |
| IL183373A0 (en) | 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof | |
| FR2998298B1 (fr) | Synthese de sels d’imidazo[1,2-a]pyrazin-4-ium pour la synthese du 1,4,7-triazacyclononane (tacn) et de ses derives n- et/ou c-fonctionnalises | |
| EA200801494A1 (ru) | Производные оксадиазола с активностью crth2 рецептора |